IL-7Rαγc ligand immunoglobulin fusion proteins

1. An IL-7Rαγc ligand comprising:

an IL-7Rα ligand comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 1; and

an Rγc ligand comprising an amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 11.

2. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises:

an IL-7Rα ligand comprising an amino acid sequence of SEQ ID NO: 1 and

an Rγc ligand comprising an amino acid sequence of SEQ ID NO: 11.

3. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises:

an IL-7Rα ligand comprising an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 1; and

an Rγc ligand comprising an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 11.

4. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises:

an IL-7Rα ligand comprising an amino acid sequence based on SEQ ID NO: 1 and having from 1 to 5 amino acid substitutions; and

an Rγc ligand comprising an amino acid sequence based on SEQ ID NO: 11 and having from 1 to 5 amino acid substitutions.

5. The IL-7Rαγc ligand of claim 1 , wherein each of the IL-7Rα ligand and the Rγc ligand independently comprises from 1 to 6 glycines (G) on the N-terminus, on the C-terminus, or on both the N-terminus and the C-terminus.

6. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rα ligand and the Rγc ligand are bound together through a ligand linker.

7. The IL-7Rαγc ligand of claim 6 , wherein the ligand linker comprises an amino acid sequence selected from any one of SEQ ID NO: 113-136.

8. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises:

an amino acid sequence of any one of SEQ ID NO: 21-26 or an amino acid sequence having greater than 70% sequence similarity to any one of SEQ ID NO: 21-26:

WGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQ (SEQ ID NO: 21)

GWGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQ (SEQ ID NO: 22)

WGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQGG (SEQ ID NO: 23)

GWGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQGG (SEQ ID NO: 24)

GGWGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQGG (SEQ ID NO: 25)

GGGWGIPWCTLDPGSLQCAWLGKH-X 1 -VVCQDWEGVELCWQGG (SEQ ID NO: 26);

and wherein X 1 is selected from an amino acid sequence of any one of SEQ ID NO: 101-143.

9. The IL-7Rαγc ligand of claim 8 , wherein X 1 is selected from of any one of SEQ ID NO: 137-143.

10. The IL-7Rαγc ligand of claim 8 , wherein X 1 has an amino acid sequence of SEQ ID NO: 139.

11. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises an amino acid sequence of any one of SEQ ID NO: 27-32, or an amino acid sequence having greater than 70% sequence similarity to any one of SEQ ID NO: 27-32.

12. The IL-7Rαγc ligand of claim 1 , wherein the IL-7Rαγc ligand comprises an amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 32.

13. An IL-7Rαγc IgG-Fc fusion fragment comprising the IL-7Rαγc ligand of claim 1 bound to an IgG-Fc fragment.

14. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IgG-Fc fragment is selected from an IgG1-Fc fragment, an IgG2-Fc fragment, and an IgG4-Fc fragment.

15. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IgG-Fc fragment is an IgG2-Fc fragment.

16. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IL-7Rαγc ligand is bound to the IgG-Fc fragment through an IgG-Fc linker.

17. The IL-7Rαγc IgG-Fc fusion fragment of claim 16 , wherein the IgG-Fc linker comprises an amino acid sequence of any one of SEQ ID NO: 150-179.

18. The IL-7Rαγc IgG-Fc fusion fragment of claim 16 , wherein the IgG-Fc linker comprises an amino acid sequence of SEQ ID NO: 163.

19. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IL-7Rαγc IgG-Fc fusion fragment comprises an amino acid sequence having greater than 70% sequence similarity to any one of SEQ ID NO: 44-55.

20. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IL-7Rαγc IgG-Fc fusion fragment comprises an amino acid sequence of any one of SEQ ID NO: 44-55.

21. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IL-7Rαγc IgG-Fc fusion fragment comprises an amino acid sequence having greater than 70% sequence similarity to SEQ ID NO: 45.

22. The IL-7Rαγc IgG-Fc fusion fragment of claim 13 , wherein the IL-7Rαγc IgG-Fc fusion fragment comprises an amino acid sequence having SEQ ID NO: 45.

23. An IL-7Rαγc IgG-Fc fusion protein comprising:

a first IL-7Rαγc IgG-Fc fusion fragment of claim 13 ; and

a second IL-7Rαγc IgG-Fc fusion fragment of claim 13 ,

wherein the IgG-Fc of the first IL-7Rαγc IgG-Fc fusion fragment comprises a first hinge region; wherein the IgG-Fc of the second IL-7Rαγc IgG-Fc fusion fragment comprises a second hinge region; and

wherein the first IL-7Rαγc IgG-Fc fusion fragment and the second first IL-7Rαγc IgG-Fc fusion fragment are bound to each other at the first hinge region and the second hinge region through disulfide bonds.

24. The IL-7Rαγc IgG-Fc fusion protein of claim 23 , wherein the first IL-7Rαγc IgG-Fc fusion fragment and the second IL-7Rαγc IgG-Fc fusion fragment have the same amino acid sequence.

25. The IL-7Rαγc IgG-Fc fusion protein of claim 23 , wherein the first IL-7Rαγc IgG-Fc fusion fragment and the second IL-7Rαγc IgG-Fc fusion fragment comprise different amino acid sequences.

26. The IL-7Rαγc IgG-Fc fusion protein of claim 23 , wherein the first IL-7Rαγc IgG-Fc fusion fragment and the second IL-7Rαγc IgG-Fc fusion fragment comprise a different IL-7Rα ligand.

27. The IL-7Rαγc IgG-Fc fusion protein of claim 23 , wherein the first IL-7Rαγc IgG-Fc fusion fragment and the second IL-7Rαγc IgG-Fc fusion fragment comprise a different Rγc ligand.

28. A pharmaceutical composition comprising the IL-7Rαγc ligand of claim 1 .

29. A pharmaceutical composition comprising the IL-7Rαγc IgG-Fc fusion protein of claim 13 .